Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

SNSS $0.65 0.1439 +28.44%
CYTK $11.12 1.1700 +11.76%
SPHS $5.86 0.4600 +8.52%
BDSI $2.55 0.2000 +8.51%
NKTR $17.29 1.1900 +7.39%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

PVCT $0.29 -0.0200 -6.45%
TGTX $5.91 -0.4000 -6.34%
VSTM $1.40 -0.0800 -5.41%
GALE $0.44 -0.0254 -5.40%
NLNK $10.58 -0.5300 -4.77%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | Next > | Last >>

I Thought Melanoma Would Kill Me. Here’s Why It Didn’t.

(Washington Post) July 18, 2016 - New drugs arrived in time to help me, but the development process is difficult and the cost is high.
read article (free registration required) 

New on NCI's Websites for July 2016

(NCI/Cancer Currents Blog) July 15, 2016 - NCI is constantly publishing new information on its websites, so periodically we provide updates on new content of interest to the cancer community.
read article 

Senators Introduce Bill to Revise Electronic Health Record Program

(ACCC) July 14, 2016 - On July 13, 2016, a group of Senate Republicans introduced The Electronic Health Record Regulatory Relief Act (S. 3173) that would dramatically reform the $34 billion federal Medicare program that rewards doctors and hospitals for adopting electronic health record (EHR) systems.
read article 

China Approves Use Of GSK Vaccine Cervarix For Cervical Cancer

(Reuters) July 18, 2016 - Drugmaker GlaxoSmithKline Plc said on Monday the China Food and Drug Administration (CFDA) has approved its human papillomavirus (HPV) vaccine, Cervarix, for use in the country to help women fight cervical cancer.
read article 

Top Cancer Hospital May Enter San Diego Market

(San Diego Union-Tribune) July 17, 2016 - A potential partnership between Scripps Health and MD Anderson could bring one of the best-known names in cancer care to San Diego County.
read article 

NSW Government to Collaborate With United States On Cancer Research

(Sydney Morning Herald [Australia]) July 18, 2016 - The NSW government has signed a deal worth millions of dollars which will see ongoing collaboration in cancer research with the United States.
read article 

GM Cancer Center Receives $1Mil to Promote Health Equity Through Patient-Provider Training Program

(George Washington) July 18, 2016 - With support from the Pfizer Foundation, the GW Cancer Center will train patients and providers on how to improve communications for better health.
read press release 

TK216 Receives Orphan Drug Designation for the Treatment of Ewing Sarcoma, a Rare Pediatric Cancer

(Oncternal Therapeutics) July 13, 2016 — Oncternal Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapies for rare and common malignancies, today announced that TK216 has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of Ewing sarcoma.
read corporate press release 

bluebird bio Presents megaTAL Genome Editing Data at American Society of Hematology (ASH) Workshop on Genome Editing

(TheStreet) July 18, 2016 - bluebird bio, Inc., a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced the presentation of pre-clinical data from its megaTAL genome editing platform at the ASH Workshop on Genome Editing, held July 14-15 in Washington, D.C.
read article 

Cancer Genetics Inc. Selected by H3 Biomedicine Inc., to Provide Biomarker Discovery and Testing for a Global Drug Development Program in Hematologic Cancers

(Yahoo! Finance) July 18, 2016 - Cancer Genetics, Inc. announces that it has been chosen by H3 Biomedicine Inc. (H3), a biopharmaceutical company specializing in the discovery and development of precision medicines for oncology, and a member of the Eisai Group, to provide clinical biomarker services for H3's lead oncology drug candidate H3B-8800.
read article 

Doctors Should Bone Up on CT Scan Cancer Risks

(U.S. News & World Report/HealthDay News) July 15, 2016 - Doctors routinely order CT scans as diagnostic tools. But many are ill-informed about the cancer risks associated with this imaging technology, a new study suggests.
read article 

Scientists Trace Origin Cell of Bone and Soft Tissue Tumors, Test Drug Target

(Duke Medicine) July 14, 2016 - Scientists at Duke Health are part of a team that has discovered a type of cell surrounding blood vessels can also serve as a starting point for sarcoma, a form of cancer that occurs in bones and connective tissues.
read press release 

Mount Sinai Researchers Develop Simple Method to Characterize Immune Cells in Tumors

(Mount Sinai Hospital) July 14, 2016 - Researchers at The Tisch Cancer Institute (TCI) at the Icahn School of Medicine at Mount Sinai have developed a new method of analyzing multiple tissue markers using only one slide of a tumor section to better understand immune response occurring locally.
read press release 

Adjuvant Chemotherapy in Early-Stage Colon Cancer May Improve Survival

(UIC News Center) July 15, 2016 - Researchers from the University of Illinois at Chicago have found an association between the use of adjuvant chemotherapy in stage 2 colon cancer and improved survival — regardless of a patient’s age or risk, or even of the specific chemotherapy administered.
read press release 

Upfront Immunotherapy for Lung Cancer? Not Yet

(Medscape Medical News) July 14, 2016 - Two new immunotherapies are approved for use in patients who progress while receiving standard chemotherapy. Is it time to use these drugs first, before or with chemotherapy?
read article (free registration required) 

Study: Five-Year Survival Data Suggest Brentuximab Vedotin Potentially Curative in Some Hodgkin Lymphoma Patients with Limited Treatment Options

(ASH) July 18, 2016 - Five-year survival data published online today in Blood, the Journal of the American Society of Hematology (ASH), suggest that the targeted therapy brentuximab vedotin may have cured some Hodgkin lymphoma patients whose disease has persisted despite receiving previous therapies.
read press release 

AZ’ Tagrisso Hits Goals In Second-Line Lung Cancer Trial

(PharmaTimes [UK]) July 18, 2016 - A Phase III trial assessing AstraZeneca's lung cancer drug Tagrisso has met its primary endpoint in showing superior progression-free survival compared to standard chemotherapy.
read article 

Roche Blood Cancer Medicine Fails to Show Major Improvement

(Bloomberg) July 18, 2016 - Swiss drugmaker Roche Holding AG said its blood cancer medicine Gazyva failed to show a significant improvement over its best-seller Rituxan, a setback in efforts to defend the aging blockbuster against copycats.
read article 

Genentech Provides Update on Phase III Study of Gazyva® in People With Previously Untreated Diffuse Large B-Cell Lymphoma

(Morningstar) July 18, 2016 - GOYA study did not meet its primary endpoint of improvement in progression-free survival with Gazyva plus CHOP chemotherapy versus Rituxan plus CHOP chemotherapy.
read article 

Tagrisso Met Primary Endpoint In Phase III 2nd-Line Lung Cancer Trial

(AstraZeneca plc) July 18, 2016 - Tagrisso demonstrated superior progression-free survival compared to standard platinum-based chemotherapy, with a safety profile consistent with previous trials; first randomised trial to evaluate the clinical benefit of an EGFR T790M medicine, and data are consistent with those supporting Tagrisso approvals.
read corporate press release 

Bristol-Myers Squibb Announces Regulatory Updates for Opdivo (nivolumab) in Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

(BMS) July 18, 2016 - Bristol-Myers Squibb Company announced today U.S. and European marketing applications to expand the use of Opdivo for patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were accepted for filing by the U.S. Food and Drug Administration (FDA) and validated by the European Medicines Agency (EMA).
read corporate press release 

FDA Releases Draft Guidance Outlining Principles of Drug/Diagnostic Codevelopment

(GenomeWeb) July 14, 2016 - The US Food and Drug Administration today released a draft guidance on the principles of drug and diagnostic codevelopment as a practical framework for sponsors advancing a therapeutic alongside a companion test and for agency staff reviewing these products.
read article (free registration required) 

Congress Passes Opioid Abuse Bill

(NBC News/Associated Press) July 13, 2016 - Congress sent President Barack Obama a compromise bill Wednesday aimed at curbing abuse of heroin and other drugs, a nationwide epidemic that kills more than 100 Americans every day.
read article 

Zika Can Spread Sexually From Women to Men

(TIME) July 15, 2016 - The first case of Zika spreading sexually from a woman to a man has been documented in New York City, according to a new report from the U.S. Centers for Disease Control and Prevention.
read article 

FDA Staff Split Over Suicide Risk of Valeant's Psoriasis Drug

(Bloomberg) July 15, 2016 - The drug, brodalumab, works to treat moderate to severe plaque psoriasis, yet the safety issues are complex, according to a report released Friday by Food and Drug Administration staff.
read article